James Zachary
Urology · Safety Harbor, FLNPI 1194717306
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,933 of the $7,778 with a category attached, or 63.4%. 32 manufacturers reported payments, led by Teleflex LLC at 25.6% of the total. Reporting peaked in 2022 at $2,451 and has fallen 94.5% since, to $135 in 2024.
Across 194 payments — averaging $40.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$2K
- Bayer$2K
- Johnson & Johnson$498
- Dendreon Pharmaceuticals LLC$468
- Astellas Pharma US Inc$408
- AstraZeneca$314
- plus $2K from 26 others
Across 49 payments — averaging $6852.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Urovant Sciences Inc$218K
- Sumitomo Pharma America, Inc.$118K
What the payments were for
- Consulting fees$1,53220%
- Travel & lodging$1,10414%
- Food & beverage$4,93363%
- Education$2093%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 12 | $1,990 |
| Bayer | 12 | $1,690 |
| Johnson & Johnson | 35 | $498 |
| Dendreon Pharmaceuticals LLC | 12 | $468 |
| Astellas Pharma US Inc | 19 | $408 |
| AstraZeneca | 6 | $314 |
| Neotract Inc. | 6 | $269 |
| AbbVie(2 entities) | 13 | $209 |
| Axonics, Inc. | 4 | $187 |
| Amgen | 5 | $166 |
| Endo Pharmaceuticals Inc. | 8 | $159 |
| Sumitomo Pharma America, Inc. | 8 | $157 |
| Pfizer | 9 | $155 |
| Blue Earth Diagnostics | 3 | $145 |
| Healthtronics Stone Solutions, LLC | 1 | $111 |
| Janssen Scientific Affairs, LLC | 1 | $110 |
| Coloplast | 5 | $109 |
| Sun Pharmaceutical Industries Inc. | 6 | $105 |
| Tolmar Pharmaceuticals, Inc. | 4 | $75 |
| Myovant Sciences Inc. | 4 | $68 |
| Boston Scientific | 3 | $65 |
| Merck | 3 | $56 |
| Novartis | 2 | $43 |
| Urovant Sciences Inc | 2 | $43 |
| Sanofi | 2 | $35 |
| Tolmar, Inc. | 2 | $34 |
| Verity Pharmaceuticals Inc. | 2 | $30 |
| Accord Healthcare, Inc. | 1 | $25 |
| Telix Pharmaceuticals | 1 | $17 |
| Travere Therapeutics, Inc. | 1 | $14 |
| Photocure Inc | 1 | $13 |
| Antares Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,778 in reported general payments places this provider in the 70th percentile of 935 urology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 40 | $658,304 |
| MyrbetriqMirabegron | 44 | $34,859 |
| GemtesaVibegron | 19 | $11,284 |
| Tamsulosin Hcl | 313 | $3,708 |
| Potassium Citrate ErPotassium Citrate | 29 | $2,808 |
| Finasteride | 179 | $1,984 |
| Oxybutynin Chloride ErOxybutynin Chloride | 36 | $1,285 |
| Solifenacin Succinate | 19 | $1,008 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 39 | $822 |
| Anastrozole | 33 | $102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $408 | $693,16384 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $157 | $11,28419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 935 urology providers in Florida.
Other urology in Safety Harbor
- Paulas VyasSafety Harbor$49K
- Paul PeritoCoral Gables$3.6M
- Scott SellingerTallahassee$2.3M
- Mark Anthony GonzalgoMiami$1M
- Edward GheilerHialeah$655K
- Rolando RiveraNaples$437K
- Matthew ErcolaniVenice$416K
- Olubayo TojuolaOrlando$283K
- Juan SuarezCoral Gables$276K
- Michael McDonaldCelebration$272K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.